 BOSTON and ATLANTA, March 8, 2022 PRNewswire -- Inhibikase Therapeutics, Inc. Nasdaq: IKT Inhibikase, a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinsons disease and related disorders, today announced that Dr. Milton Werner, Ph.D., President Chief Executive Officer of Inhibikase, will give an oral presentation at the ADPDTM, Alzheimers Parkinsons Diseases Conference being held in Barcelona, Spain from March 15-20, 2022. 